Cloudbreak Pharma Inc. (2592)

Overview

Cloudbreak Pharma Inc. is a clinical-stage biotechnology firm dedicated to the development of innovative ophthalmic drugs aimed at treating chronic eye diseases. Established in 2015 and based in Irvine, California, the company is committed to creating advanced treatment solutions for conditions that currently offer limited therapeutic alternatives. Cloudbreak Pharma's primary objective is to enhance both the vision and overall quality of life for patients suffering from various ocular disorders. The company’s talented research and development team possesses extensive expertise in ocular drug development, focusing on the underlying biological mechanisms of several eye conditions.

A standout element of Cloudbreak Pharma's portfolio is its lead candidate, CBT-001. This investigational eye drop therapy shows promise in its ability to slow or potentially halt the progression of pterygium, a prevalent eye condition. In order to facilitate the commercialization and production of its innovative products, the company has established multiple licensing agreements, particularly within key Asian markets. Moreover, Cloudbreak Pharma's pipeline is comprehensive, featuring additional drug candidates targeting conditions such as meibomian gland dysfunction, pinguecula, diabetic macular edema, and presbyopia, reiterating its deep commitment to addressing existing gaps in eye health care. Through its research and development endeavors, Cloudbreak Pharma plays a crucial role in the global advancement of ophthalmic therapeutics.

Products and Services

• CBT-001:

  This investigational eye drop therapy is designed specifically to address pterygium by potentially slowing or halting its progression. The drug aims to improve patient outcomes through enhanced visual acuity and by addressing the physiological challenges posed by this common ocular condition.

• Meibomian Gland Dysfunction Therapy:

  Cloudbreak Pharma is actively developing therapeutic options to treat meibomian gland dysfunction, which affects tear film stability and can lead to discomfort and impaired vision. Targeting this condition underscores the company's dedication to fulfilling critical needs in ocular health.

• Pinguecula Treatment:

  In addition to pterygium, Cloudbreak Pharma is advancing treatments aimed at addressing pinguecula, a growth on the conjunctiva that can cause irritation. The company's research focuses on providing safe and effective solutions for patients afflicted by this disorder.

• Diabetic Macular Edema Medication:

  Diabetic macular edema is a sight-threatening complication of diabetes. Cloudbreak Pharma is developing therapies specifically aimed at reducing the impact of this condition, thus working toward its goal of improving diabetic patients' vision and quality of life.

• Presbyopia Solutions:

  Recognizing the aging population's needs, Cloudbreak Pharma is investigating therapeutic options for presbyopia. These innovative solutions aim to enhance near vision for individuals reaching middle age and beyond, addressing a common vision impairment.